• 1
    Castaldo G, D’Argenio V, Nardiello P, Zarrilli F, Sanna V, Rocino A, Coppola A, Di Minno G, Salvatore F. Haemophilia A: molecular insights. Clin Chem Lab Med 2007; 45: 45061.
  • 2
    Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol 2006; 13: 3017.
  • 3
    Yarovoi H, Kufrin D, Eslin DE, Zhu H, Wilcox DA, Camire R, Fakharzadeh SS, Kowalska MA, Montgomery RR, Poncz M. Factor VIII ectopically expressed in platelets. Efficacy in hemophilia A treatment. Blood 2003; 102: 400613.
  • 4
    Yarovoi H, Nurden AT, Montgomery RR, Nurden P, Poncz M. Intracellular interaction of Von Willebrand Factor and Factor VIII depends on cellular context: lessons from platelet expressed Factor VIII. Blood 2005; 105: 46746.
  • 5
    Bi L, Lawler AM, Antonarakis SE, High KA, Gearhart JD, Kazazian HH Jr. Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A. Nat Genet 1995; 10: 11921.
  • 6
    Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006; 116: 197482.
  • 7
    High KA. The leak stops here: platelets as delivery vehicles for coagulation factors. J Clin Invest 2006; 116: 18402.
  • 8
    Andrews N. Putting platelets to work to circumvent hemophilia inhibitors. Hematologist 2006; 3: 8.
  • 9
    Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV. Immune response against therapeutic factor VIII in hemophilia A patients – a survey of probable risk factors. Immunol Lett 2007; 110: 238.
  • 10
    Mathew P. Current opinion on inhibitor treatment options. Semin Hematol 2006; 43: S813.
  • 11
    Fay WP, Parker AC, Ansari MN, Zheng X, Ginsburg D. Vitronectin inhibits the thrombotic response to arterial injury in mice. Blood 1999; 93: 182530.
  • 12
    Pittman DD, Alderman EM, Tomkinson KN, Wang JH, Giles AR, Kaufman RJ. Biochemical, immunological, and in vivo functional characterization of B-domain-deleted factor VIII. Blood 1993; 81: 292535.
  • 13
    Hashimoto Y, Ware J. Identification of essential GATA and Ets binding motifs within the promoter of the platelet glycoprotein Ib alpha gene. J Biol Chem 1995; 270: 245329.
  • 14
    Fujita H, Hashimoto Y, Russell S, Zieger B, Ware J. In vivo expression of murine platelet glycoprotein Ibalpha. Blood 1998; 92: 48895.
  • 15
    Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 18119.
  • 16
    Villard S, Piquer D, Raut S, Leonetti JP, Saint-Remy JM, Granier C. Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8. J Biol Chem 2002; 277: 272329.
  • 17
    Verbruggen B, Novakova I, Wessels H, Boezeman J, Van Den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 24751.
  • 18
    Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem 1996; 271: 2742431.
  • 19
    Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 116015.
  • 20
    Hsu TC, Pratt KP, Thompson AR. The factor VIII C1 domain contributes to platelet binding. Blood 2008; 111: 2008.
  • 21
    Handagama P, Rappolee DA, Werb Z, Levin J, Bainton DF. Platelet alpha-granule fibrinogen, albumin, and immunoglobulin G are not synthesized by rat and mouse megakaryocytes. J Clin Invest 1990; 86: 13648.
  • 22
    George JN, Saucerman S, Levine SP, Knieriem LK, Bainton DF. Immunoglobulin G is a platelet alpha granule-secreted protein. J Clin Invest 1985; 76: 20205.
  • 23
    Millward TA, Heitzmann M, Bill K, Langle U, Schumacher P, Forrer K. Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. Biologicals 2008; 36: 417.
  • 24
    Kufrin D, Eslin DE, Bdeir K, Murciano J-C, Kuo A, Kowalska MA, Degen JL, Sachais BS, Cines DB, Poncz M. Anti-thrombotic thrombocytes. Ectopic expression of urokinase-type plasminogen activator in platelets. Blood 2003; 102: 92633.
  • 25
    Mordenti J, Osaka G, Garcia K, Thomsen K, Licko V, Meng G. Pharmacokinetics and interspecies scaling of recombinant human factor VIII. Toxicol Appl Pharmacol 1996; 136: 758.
  • 26
    Shi Q, Fahs SA, Wilcox DA, Kuether EL, Weiler H, Montgomery RR. In the presence of pre-existing factor VIII (FVIII) immunity, hematopoietic stem cells (HSC) that are genetically modified to express FVIII in platelets were successfully transplanted into hemophilic mice under myeloablative and various non-myeloablative conditions. Blood 2007; 110: 236a.
  • 27
    Italiano J, Richardson JL, Folkman J, Klement G. Blood platelets organize pro- and anti-angiogenic factors into separate, distinct alpha granules: implications for the regulation of angiogenesis. Blood 2006; 108: 120a.
  • 28
    Olson PS, Ljungqvist U, Bergentz SE. Analysis of platelet, red cell and fibrin content in experimental arterial and venous thrombi. Thromb Res 1974; 5: 119.
  • 29
    Furie BC, Furie B. Tissue factor pathway vs. collagen pathway for in vivo platelet activation. Blood Cells Mol Dis 2006; 36: 1358.
  • 30
    Spira J, Plyushch OP, Andreeva TA, Andreev Y. Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes. Blood 2006; 108: 366873.